New research uncovers how cancers with common mutation develop resistance to targeted drugs
Multiple acquired resistance mechanisms discovered for cancers with KRASG12C mutation after treatment with KRASG12C inhibitors; Results point to need for new drugs targeting KRAS and new combination therapies
A new study by Dana-Farber Cancer Institute researchers has given scientists their first look at the genomic landscape of tumors that have grown resistant to drugs targeting the abnormal KRASG12C protein. Their work shows that, far from adopting a common route to becoming resistant, the cells take a strikingly diverse set of avenues, often several at a time.
The findings, reported online today in the END
The findings, reported online today in the END